DYNAMICS OF PLASMA CONCENTRATION OF SHORT-ACTING ERYTHROPOIESIS STIMULATING AGENTS AT TREATMENT OF THE MYELOTOXIC ANEMIA IN PATIENTS WITH TERMINAL CHRONIC RENAL INSUFFICIENCY
- Autores: Yampolsky MA1, Berdnikov AV1, Yampol'skiy M.A.1, Berdnikova A.V.1
-
Afiliações:
- Edição: Nº 18-19 (2010)
- Páginas: 73-76
- Seção: Articles
- URL: https://journals.eco-vector.com/2073-4034/article/view/278714
- ID: 278714
Citar
Texto integral
Resumo
Comparison of dynamics of concentration of various short-acting erythropoesis stimulating agents (ESA) used for correction of anemia in patients with terminal chronic renal insufficiency (tCRI) is presented. The study enrolled 50 tCRI patients which were treated by hemodialysis during 6 months to 5 years. The study has shown the similar bioavailability of various short-acting ESA - Eprex, Eralfon and Recormon, which were used in combination with iron preparations for correction of anemia in CRI patients. It suggests equal efficiency of intravenous administration of these agents in patients with tCRI.
Palavras-chave
Bibliografia
- Perеlman RL, Finkelstein FO, Liu L, et al. Quality of life in chronic kidney disease a cross-sectional analysis in the Renal Research Institute-CKD study. American journal of kidney diseases. 2005;(45):658-66.
- Silverberg DS, Wexler D, Blum M, et al. Erythropoietin should be part of congestive heart failure management. Kidney international 2003;(87 Suppl.):40-4.
- Donnelly S. Why is erythropoietin made in the kidney? The kidney functions as a critmeter. Am J Kidney Dis 2001;(38):415-25.
- Ratcliffe PJ. Molecular biology of erythropoietin. Kidney International 1993;(44):887-904.
- Priyadarshi A, Shapiro JI. Erythropoietin resistance in the treatment of the anemia of chronic renal failure. Seminars in dialysis 2006;19(4):273-78.
- Locatelli F, Covic A, Eckardt K-U, et al. Anaemia management in patients with chronic kidney disease: a position statement by the Anaemia Working Group of European Renal Best Practice (ERBP). Nephrology dialysis transplantation 2009(24):348-54.
- Mennini T, De Paola M, Bigini P, et al. Nonhematopoietic Erythropoietin Derivatives Prevent Motoneuron Degeneration In Vitro and In Vivo. Molecular medicine 2006;12(7-8):153-60.
- Fantacci M, Bianciardi P, Caretti A. Carbamylated erythropoietin ameliorates the metabolic stress induced in vivo by severe chronic hypoxia. Proc Natl Acad Sci 2006;103(46):17531-36.
- Walsh TS, Saleh ЕЕ. Anaemia during critical illness. Br J Anaesth 2006;97(3):278-91.
- Sharples EJ, Yaqoob MM. Erythropoietin and acute renal failure. Semin Nephrol 2006;26(4):325-31.
Arquivos suplementares
